ArticlePloS one2017
Metabolic Imaging of Head and Neck Cancer Organoids.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 74 citations in OpenAlex.
- Submicromolar imaging of intrinsic chromophores by two-photon photothermal microscopy captures mitochondrial response to chemotherapy.Science advances · 2026Article
- Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids.Cancer research · 2025Article
- Optical phenotyping using label-free microscopy and deep learning.Biophotonics discovery · 2025Article
- Three-dimensional in vitro models in head and neck cancer: current trends and applications.Medical oncology (Northwood, London, England) · 2025Review
- Merging metabolic modeling and imaging for screening therapeutic targets in colorectal cancer.NPJ systems biology and applications · 2025Article
- Measuring Metabolic Changes in Cancer Cells Using Two-Photon Fluorescence Lifetime Imaging Microscopy and Machine-Learning Analysis.Journal of biophotonics · 2025Article
- Article
- Merging Metabolic Modeling and Imaging for Screening Therapeutic Targets in Colorectal Cancer.bioRxiv : the preprint server for biology · 2024Article
- Simultaneous assessment of NAD(P)H and flavins with multispectral fluorescence lifetime imaging microscopy at a single excitation wavelength of 750 nm.Journal of biomedical optics · 2024Article
- The Use of Patient-Derived Organoids in the Study of Molecular Metabolic Adaptation in Breast Cancer.International journal of molecular sciences · 2024Review
- Insights into metabolic heterogeneity of colorectal cancer gained from fluorescence lifetime imaging.eLife · 2024Article
- Challenges of Spatially Resolved Metabolism in Cancer Research.Metabolites · 2024Review
- SOX2 and OCT4 mediate radiation and drug resistance in pancreatic tumor organoids.Cell death discovery · 2024Article
- Fanconi anemia-isogenic head and neck cancer cell line pairs: A basic and translational science resource.International journal of cancer · 2023Article
- Review
- Aligning Small Datasets Using Domain Adversarial Learning: Applications in Automated in Vivo Oral Cancer Diagnosis.IEEE journal of biomedical and health informatics · 2023Article
- The applications and techniques of organoids in head and neck cancer therapy.Frontiers in oncology · 2023Review
- Single cell metabolism: current and future trends.Metabolomics : Official journal of the Metabolomic Society · 2022Review
- Technologies to Assess Drug Response and Heterogeneity in Patient-Derived Cancer Organoids.Annual review of biomedical engineering · 2022Review
- Label-free sensing of cells with fluorescence lifetime imaging: The quest for metabolic heterogeneity.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Head and neck cancer patients suffer from toxicities, morbidities, and mortalities, and these ailments could be minimized through improved therapies. Drug discovery is a long, expensive, and complex process, so optimized assays can improve the success rate of drug candidates. This study applies optical imaging of cell metabolism to three-dimensional in vitro cultures of head and neck cancer grown from primary tumor tissue (organoids). This technique is advantageous because it measures cell metabolism using intrinsic fluorescence from NAD(P)H and FAD on a single cell level for a three-dimensional in vitro model. Head and neck cancer organoids are characterized alone and after treatment with standard therapies, including an antibody therapy, a chemotherapy, and combination therapy. Additionally, organoid cellular heterogeneity is analyzed quantitatively and qualitatively. Gold standard measures of treatment response, including cell proliferation, cell death, and in vivo tumor volume, validate therapeutic efficacy for each treatment group in a parallel study. Results indicate that optical metabolic imaging is sensitive to therapeutic response in organoids after 1 day of treatment (p<0.05) and resolves cell subpopulations with distinct metabolic phenotypes. Ultimately, this platform could provide a sensitive high-throughput assay to streamline the drug discovery process for head and neck cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.